These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 23802404)

  • 1. Nanomaterials in cancer-therapy drug delivery system.
    Zhang G; Zeng X; Li P
    J Biomed Nanotechnol; 2013 May; 9(5):741-50. PubMed ID: 23802404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.
    Piktel E; Niemirowicz K; Wątek M; Wollny T; Deptuła P; Bucki R
    J Nanobiotechnology; 2016 May; 14(1):39. PubMed ID: 27229857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug delivery/imaging multifunctionality of mesoporous silica-based composite nanostructures.
    Chen Y; Chen H; Shi J
    Expert Opin Drug Deliv; 2014 Jun; 11(6):917-30. PubMed ID: 24746014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review.
    Kamath PR; Sunil D
    Mini Rev Med Chem; 2017; 17(15):1457-1487. PubMed ID: 28245780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomaterials for cancer therapy: current progress and perspectives.
    Cheng Z; Li M; Dey R; Chen Y
    J Hematol Oncol; 2021 May; 14(1):85. PubMed ID: 34059100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomaterials multifunctional behavior for enlightened cancer therapeutics.
    Raju GSR; Dariya B; Mungamuri SK; Chalikonda G; Kang SM; Khan IN; Sushma PS; Nagaraju GP; Pavitra E; Han YK
    Semin Cancer Biol; 2021 Feb; 69():178-189. PubMed ID: 31419527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-sensitive nano-systems for drug delivery in cancer therapy.
    Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
    Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface engineered multifunctional nano-systems for localised drug delivery against thyroid cancer: A review of current practices.
    Zhang Y; Tang N; Zhou H; Zhu Y
    Biomed Pharmacother; 2024 Jul; 176():116840. PubMed ID: 38820975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs.
    Joanitti GA; Ganassin R; Rodrigues MC; Figueiro Longo JP; Jiang CS; Gu J; Leal Pinto SM; Almeida Dos Santos MF; de Azevedo RB; Muehlmann LA
    Mini Rev Med Chem; 2017; 17(3):224-236. PubMed ID: 27739361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosize drug delivery system.
    Mukherjee B
    Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications.
    Ruttala HB; Ramasamy T; Madeshwaran T; Hiep TT; Kandasamy U; Oh KT; Choi HG; Yong CS; Kim JO
    Arch Pharm Res; 2018 Feb; 41(2):111-129. PubMed ID: 29214601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.
    Hayashi JY; Tamanoi F
    Enzymes; 2017; 42():153-172. PubMed ID: 29054269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimuli-responsive polymeric nanoparticles for nanomedicine.
    Crucho CI
    ChemMedChem; 2015 Jan; 10(1):24-38. PubMed ID: 25319803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic and diagnostic applications of nanoparticles.
    Youns M; Hoheisel JD; Efferth T
    Curr Drug Targets; 2011 Mar; 12(3):357-65. PubMed ID: 20955146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle therapeutics: Technologies and methods for overcoming cancer.
    Cerqueira BB; Lasham A; Shelling AN; Al-Kassas R
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):140-51. PubMed ID: 26515260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second generation liposomal cancer therapeutics: transition from laboratory to clinic.
    Sen K; Mandal M
    Int J Pharm; 2013 May; 448(1):28-43. PubMed ID: 23500602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
    Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
    Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.